View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 4, 2022

Jubilant receives FDA IND clearance for Phase I/II solid tumour trial

The two-part trial will analyse the safety, pharmacokinetics, optimal dosing and initial activity of JBI-778.

Jubilant Therapeutics has received the US Food and Drug Administration (FDA) clearance for the Investigational New Drug application (IND) to start a Phase I/II clinical trial of JBI-778 to treat solid tumours.

The therapy is intended for treating solid tumours with brain metastases and primary brain tumours including high-grade glioma.

The open-label, two-part dose escalation and expansion trial will analyse the safety profile, pharmacokinetics, optimal dosing and initial activity of JBI-778. 

Subjects with stable brain metastasis whose disease did not respond to previous prior standard therapy will be part of the dose escalation phase.

Patients with active brain metastases and high-grade gliomas will be included in the expansion cohorts.

JBI-778 is an oral brain penetrant and selective inhibitor of protein arginine methyl transferase 5 (PRMT5). 

As against current PRMT5 inhibitors, it has a mechanism of action by being substrate-competitive and S-adenosylmethoinine (SAM) cooperative.

This mechanism along with an improved brain exposure facilitates targeting of both primary brain tumours and CNS metastasis. 

JBI-778 is said to be the second, highly selective oral drug candidate of the company to enter clinics. 

Jubilant Therapeutics CEO Syed Kazmi said: “JBI-778 was engineered by our drug discovery team to be a PRMT5 substrate-competitive and brain penetrant drug candidate to address primary brain tumours and brain metastases which currently have limited treatment options. 

“In addition to JBI-778, we are also advancing an oral brain penetrant PDL1 inhibitor, JBI 2174, which is on the IND-track to potentially treat primary CNS cancers among others.”

In April this year, the company dosed the first subject in a Phase I/II trial of JBI-802 in advanced solid tumour patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena